Syneos Health, Inc.

NasdaqGS:SYNH Rapporto sulle azioni

Cap. di mercato: US$4.5b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Syneos Health Gestione

Gestione criteri di controllo 1/4

Syneos Health's Il CEO è Michelle Keefe, nominato in Apr2022, e ha un mandato di 1.42 anni. la retribuzione annua totale è $ 8.89M, composta da 9.7% di stipendio e 90.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.034% delle azioni della società, per un valore di $ 1.53M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.7 anni e 2.3 anni.

Informazioni chiave

Michelle Keefe

Amministratore delegato

US$8.9m

Compenso totale

Percentuale dello stipendio del CEO9.7%
Mandato del CEO1.4yrs
Proprietà del CEO0.03%
Durata media del management2.7yrs
Durata media del Consiglio di amministrazione2.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 29
Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Mar 10
Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Feb 20
Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Dec 20
Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

Nov 28
Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Nov 01
Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Syneos, Datavant expand partnership on data analytics for clinical trials

Oct 11

Syneos Health falls 13% after update on outlook

Sep 13

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Sep 08
When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Aug 22
Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Syneos Health Q2 2022 Earnings Preview

Aug 01

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Jul 19
With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Syneos: Upside Could Be Priced In, Valuations Unsupportive

Jul 15

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Jun 18
Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Jun 03
Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

May 19
We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Apr 08
Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Mar 27

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 05
Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Feb 18
Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Feb 03
Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Jan 04
With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022

Dec 03

Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Dec 03
Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Michelle Keefe rispetto agli utili di Syneos Health?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2023n/an/a

US$71m

Mar 31 2023n/an/a

US$148m

Dec 31 2022US$9mUS$862k

US$266m

Sep 30 2022n/an/a

US$287m

Jun 30 2022n/an/a

US$278m

Mar 31 2022n/an/a

US$242m

Dec 31 2021US$2mUS$567k

US$235m

Sep 30 2021n/an/a

US$251m

Jun 30 2021n/an/a

US$236m

Mar 31 2021n/an/a

US$198m

Dec 31 2020US$2mUS$522k

US$193m

Sep 30 2020n/an/a

US$192m

Jun 30 2020n/an/a

US$187m

Mar 31 2020n/an/a

US$195m

Dec 31 2019US$2mUS$550k

US$131m

Compensazione vs Mercato: La retribuzione totale di Michelle ($USD 8.89M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.76M ).

Compensazione vs guadagni: La retribuzione di Michelle è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Michelle Keefe (56 yo)

1.4yrs

Mandato

US$8,889,996

Compensazione

Ms. Michelle Keefe serves as Chief Executive Officer at Syneos Health, Inc since April 29, 2022 and serves as its Director since 2022. She served as President of Medical Affairs and Commercial Solutions fo...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Michelle Keefe
CEO & Director1.4yrsUS$8.89m0.034%
$ 1.5m
Michael Brooks
Chief Operating Officer1.4yrsUS$6.04m0.018%
$ 810.0k
Jonathan Olefson
General Counsel & Corporate Secretary4.8yrsUS$3.52m0.014%
$ 617.4k
Christian Tucat
Chief Business Officer5yrsUS$2.62m0.011%
$ 502.0k
Jason Meggs
Consultantless than a yearUS$3.19m0.039%
$ 1.8m
Michael Bonello
Chief Financial Officerless than a yearNessun datoNessun dato
Donna Kralowetz
Senior VP of Finance & Chief Accounting Officer2.7yrsNessun dato0.0029%
$ 130.6k
Baba Shetty
President of Technology & Data Solutions1.4yrsNessun datoNessun dato
Judith Ng-Cashin
Chief Scientific Officer7.5yrsNessun datoNessun dato
Larry Pickett
Chief Information & Digital Officer2.8yrsNessun datoNessun dato
Ronnie Speight
Senior Vice President of Investor Relationsno dataNessun datoNessun dato
Kristen Spensieri
Global Head of Corporate Communications & Marketing6.1yrsNessun datoNessun dato

2.7yrs

Durata media

52.5yo

Età media

Gestione esperta: Il team dirigenziale di SYNH è considerato esperto (durata media dell'incarico 2.7 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Michelle Keefe
CEO & Director1.7yrsUS$8.89m0.034%
$ 1.5m
Kenneth Meyers
Independent Director6.9yrsUS$370.77k0.019%
$ 865.7k
William Klitgaard
Independent Directorless than a yearUS$182.56k0%
$ 0
Matthew Monaghan
Independent Director6.9yrsUS$322.77k0.019%
$ 850.1k
Alfonso Zulueta
Independent Director1.7yrsUS$351.39k0.0034%
$ 150.2k
John Dineen
Independent Chairman4.8yrsUS$483.27k0.022%
$ 972.7k
David Wilkes
Independent Director2.3yrsUS$308.52k0.0048%
$ 213.5k
Bernadette Connaughton
Independent Director3.8yrsUS$307.77k0.0096%
$ 426.2k
Barbara Bodem
Independent Director1.7yrsUS$369.53k0.0034%
$ 151.6k

2.3yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di SYNH non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.